


## Roslin 2 bromide

## Chemical Properties

CAS No. :	29574-21-8
Formula:	C <sub>13</sub> H <sub>19</sub> BrN <sub>4</sub>
Molecular Weight:	311.22
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.

Br<sup>-</sup>

## Biological Description

Description	Roslin 2 bromide (Benzylhexamethylenetetramine bromide) is a p53 reactivator that disrupts the binding of FAK and p53, exhibiting anticancer effects.
Targets(IC50)	FAK,p53,MDM-2/p53
In vitro	Roslin 2 bromide reduces cancer cell viability and clonogenicity in a p53-dependent manner[1].
In vivo	Roslin 2 bromide (60 mg/kg; i.p) significantly decreased tumor growth, disrupts the complex of FAK and p53, and up-regulated p21 in HCT116 p53+/+ but not in HCT116 p53-/- xenografts[1].

## Solubility Information

Solubility	DMSO: 45 mg/mL (144.59 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.43 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.2132 mL	16.0658 mL	32.1316 mL
5 mM	0.6426 mL	3.2132 mL	6.4263 mL
10 mM	0.3213 mL	1.6066 mL	3.2132 mL
50 mM	0.0643 mL	0.3213 mL	0.6426 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Learmount J, Callaby R, Taylor M. An observational study of ewe treatments at lambing on early infection in lambs on UK sheep farms. *Vet Parasitol.* 2018 Apr 15;253:55-59. doi: 10.1016/j.vetpar.2018.02.026. Epub 2018 Feb 12. PubMed PMID: 29605004.

Takahashi M, McCartney E, Knox A, Francesch M, Oka K, Wada K, Ideno M, Uno K, Kozłowski K, Jankowski J, Gracia MI, Morales J, Kritas SK, Esteve-Garcia E, Kamiya S. Effects of the butyric acid-producing strain *Clostridium butyricum* MIYAIRI 588 on broiler and piglet zootechnical performance and prevention of necrotic enteritis. *Anim Sci J.* 2018 Mar 30. doi: 10.1111/asj.13006. [Epub ahead of print] PubMed PMID: 29603498.

Amengual Batle P, Rusbridge C, Nuttall T, Heath S, Marioni-Henry K. Feline hyperaesthesia syndrome with self-trauma to the tail: retrospective study of seven cases and proposal for integrated multidisciplinary diagnostic approach. *J Feline Med Surg.* 2018 Mar 1:1098612X18764246. doi: 10.1177/1098612X18764246. [Epub ahead of print] PubMed PMID: 29595359.

Porphyre T, Rich KM, Auty HK. Assessing the Economic Impact of Vaccine Availability When Controlling Foot and Mouth Disease Outbreaks. *Front Vet Sci.* 2018 Mar 13;5:47. doi: 10.3389/fvets.2018.00047. eCollection 2018. PubMed PMID: 29594161; PubMed Central PMCID: PMC5859371.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481